VANCOUVER, BC, September 6th, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has completed the bioproduction and batch release endotoxin screening of BVX-1021, the Company’s vaccine for SARS-CoV, which is being used in the collaboration with The Ohio […]
Author Archives: Biovaxys
VANCOUVER, BC, Aug. 9, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB,OTCQB: BVAXF) (“BioVaxys” or the “Company“) announces that it has extended the expiry date of 4,483,689 share purchase warrants with an exercise price of $0.50 and expiry date of August 26, 2022 and 1,477,291 share purchase warrants with an exercise price of $0.50 […]
VANCOUVER, British Columbia, Aug. 4, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce a non-brokered private placement (the “Private Placement”) consisting of up to 10,000,000 units (“Units”) at a price of $0.10 per Unit for total gross proceeds of up to approximately $1,000,000. Each […]
VANCOUVER, B.C., Aug. 2, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or the “Company”) further to its news release dated July 4, 2022, BioVaxys announces that it has settled an aggregate of $517,854 in debt through the issuance of common shares issued at a deemed price of $0.10 per common […]
VANCOUVER, B.C., July 4, 2022 /CNW/ – BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB,OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that is proposing to settle an aggregate of approximately $497,000 in debt through the issuance of common shares to be issued at a deemed price of $0.10 per common share. Completion of the debt settlement remains […]
VANCOUVER, BC, June 15th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that its clinical study collaborator Hospices Civils de Lyon in France (“HCL”) has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing “dry runs” of BVX-0918, a […]
VANCOUVER, BC, June 8th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that its Lyon, France-based bioproduction partner, BioElpida (“BioElpida”), has completed the creation of multiple OVCAR-3 cell banks as the next step in the GMP manufacturing process development for BVX-0918, BioVaxys’ vaccine for treatment of platinum-resistant ovarian cancer. The […]
Pan-Sarbecovirus Vaccines Identified by WHO as a Critical Need VANCOUVER, BC, June 3rd, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that The Ohio State University (“Ohio State”), its research collaborator that is jointly evaluating the Company’s novel approach for a “universal vaccine” that can treat a broad range of […]
VANCOUVER, BC, May 18th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”) has agreed to serve as a clinical study site for the Phase I study of BVX-0918, the Company’s autologous haptenized tumor cell vaccine for late-stage ovarian cancer. HCL has further agreed […]
VANCOUVER, BC, April 25, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered into an agreement with the Deaconess Research Institute (“DRI”) to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at Deaconess Health System (“Deaconess”). DRI, based in […]